Preparing Community Hospitals for CAR T’s Expansion

By choosing where to participate and working with specialist partners, community hospitals can bring more of the CAR T patient journey closer to home

1

Community hospitals grew from 23% to 45% of the US cell and gene therapy administering network between 2018 and 2025, while claims volume rose about 740%.
2

As CAR T expands to earlier cancer treatment and other diseases, care delivery is expected to become more decentralized and involve coordinated local and specialty providers.
3

Community hospitals can support diagnosis, referrals, collections, shared care, recovery monitoring, and long-term follow-up without duplicating specialized therapy-center infrastructure.
4

Community participation can progress from clinician education and referral pathways to toxicity readiness and, where appropriate, active support for therapy delivery.
5

Partnerships with established therapy programs, collection organizations, laboratories, and manufacturers can provide specialized expertise and infrastructure for community hospitals.

1